HELX

Franklin Genomic Advancements ETF
*Unless otherwise stated, data provided by FactSet.

HELX Fund Description

HELX is an actively managed portfolio of global equity securities of companies relevant to genomic discovery.

HELX Factset Analytics Insight

HELX invests in global companies benefitting from the advancements of genomic-based research techniques and technologies that are designed to extend or enhance the quality of life. The fund advisor uses fundamental research to identify and select stocks they feel best positioned to capitalize on such genomic advancements. Companies may include those that research, develop, produce or manufacture bionic devices, molecular medicine, pharmaceuticals and agricultural applications. HELX is one of the first three thematic funds to launch from Franklin Templeton.

HELX MSCI ESG Analytics Insight

Franklin Genomic Advancements ETF has an MSCI ESG Fund Rating of BBB based on a score of 4.54 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. Franklin Genomic Advancements ETF ranks in the 18th percentile within its peer group and in the 35th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

HELX MSCI FaCS and Factor Box

MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios including ETFs. The Factor Box includes 6 Factors that MSCI has identified that historically provided a return premium. On the vertical axis, the Factor Groups, are displayed and the horizontal axis displays the Factor exposure, overweight, underweight or neutral.

PERFORMANCE [as of 09/23/21] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
HELX 5.77% 19.54% 28.18% 65.73% -- -- --
HELX (NAV) 3.92% 20.50% 29.88% 71.03% -- -- --
No Underlying Index -- -- -- -- -- -- --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

HELX Summary Data

Franklin
02/25/20
Open-Ended Fund
0.50%
$36.87M
$592.54K
0.30%

HELX Portfolio Data

$47.81B
789.38
8.91
--
12/13/21
52

HELX Index Data

No Underlying Index
Proprietary
Proprietary
N/A

HELX Portfolio Management

0.50%
--
--
--

HELX Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

HELX Fund Structure

Open-Ended Fund
No
--
-- / --
N/A
N/A
Medium
Daily

HELX Factset Analytics Block Liquidity

As of 09/24/21
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of HELX. HELX is rated a 5 out of 5.

HELX Tradability

10,801
$592.54K
5,214
$291.54K
0.30%
$0.16
0.05%
0.73% / -0.30%
None
90.00%
50,000
0.10
0.01%
0.09%
0
$57.55
5

HELX Top 10 Holdings[View All]

Natera, Inc. 4.78%
3.53%
Catalent Inc 3.16%
48.39%

HELX Countries


HELX
Segment Benchmark
82.44%
--
8.70%
--
4.78%
--
3.66%
--
0.43%
--

HELX Regions


HELX
Segment Benchmark
82.44%
--
12.78%
--
4.78%
--

HELX Economic Development


HELX
Segment Benchmark
100.00%
--

HELX Performance Statistics

--
--
--
--
0.00%
N/A

HELX MSCI ESG Ratings

4.54 / 10
35.13
18.00
0.99%
1.38%
45.27

HELX Benchmark Comparison Holdings

52
--
--
0.00%

HELX Benchmark Comparison Summary


HELX
Segment Benchmark
52
--
$47.81B
--
789.38
--
8.91
--
0.06%
--
Medium
High

HELX Benchmark Comparison Market Cap Size


HELX
Segment Benchmark
62.88%
--
35.55%
--
1.57%
--
0.00%
--